PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-9.02
Negative P/E while Biotechnology median is -5.57. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
-101.89
Negative equity while Biotechnology median P/B is 3.70. Seth Klarman would investigate balance sheet restructuring potential.
-38.80
Negative FCF while Biotechnology median P/FCF is -23.88. Seth Klarman would investigate cash flow improvement potential.
-38.81
Negative operating cash flow while Biotechnology median P/OCF is -24.62. Seth Klarman would investigate operational improvement potential.
-101.89
Negative fair value while Biotechnology median is 3.70. Seth Klarman would investigate valuation model issues.
-2.77%
Negative earnings while Biotechnology median yield is -2.00%. Seth Klarman would investigate path to profitability.
-2.58%
Negative FCF while Biotechnology median yield is -1.42%. Seth Klarman would investigate cash flow improvement potential.